Standard BioTools

Standard BioTools Debt/Market Cap

The Debt to Market Capitalization Ratio of Standard BioTools (LAB) as of Nov 5, 2026 is 1.34 %. In the previous year, Debt to Market Capitalization Ratio was 0.07 % — a change of 1,829.67% (higher).

Debt/Market Cap

1.34 %

YoY

1,829.67%

Last updated:

Debt to Market Capitalization Ratio of Standard BioTools is 2025 1.34 % . Debt to Market Capitalization Ratio of Standard BioTools was 2024 0.07 % . It decreases by 1,829.67% higher compared to the previous year.

The Standard BioTools Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2018
39.96 USD
Jan 1, 2019
12.49 USD
Jan 1, 2020
12.58 USD
Jan 1, 2021
16.48 USD
Jan 1, 2022
15.07 USD
Jan 1, 2023
14.86 USD
Jan 1, 2024
0.07 USD
Jan 1, 2025
1.34 USD
The Standard BioTools Debt/Market Cap history
YEARDebt/Market CapYoY
1.34 %+1,829.67%
0.07 %-99.53%
14.86 %-1.39%
15.07 %-8.59%
16.48 %+31.00%
12.58 %+0.74%
12.49 %-68.74%
39.96 %-11.83%
45.32 %+0.10%
45.27 %+0.15%
45.20 %-0.41%
45.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Debt to Market Capitalization Ratio of Standard BioTools is 1.34 % in 2025.

Debt to Market Capitalization Ratio of Standard BioTools changed from 0.07 % to 1.34 %, representing a 1,829.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Standard BioTools with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Standard BioTools

All Key Metrics — Standard BioTools